Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS guidance · 2024-07-03Clinical Trial Update: Strategies for Adaptive Follow-up and Evaluation - Guiding Use of Indicators for De-Escalation in Multiple Sclerosis
This document outlines strategies for adaptive follow-up and evaluation and provides guidance on when to de-escalate MS treatment based on s…
-
EMA guidance · 2016-02-12Updated recommendations to minimise the risk of the rare brain infection PML with Tysabri
The EMA published updated recommendations to minimize the risk of progressive multifocal leukoencephalopathy (PML) associated with Tysabri (…
-
EMA guidance · 2015-10-23Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera
EU EMA updates recommendations to reduce risk of progressive multifocal leukoencephalopathy (PML) with Tecfidera (dimethyl fumarate).
-
EMA guidance · 2013-10-17Workshop on clinical investigation of new medicines for the treatment of multiple sclerosis takes place today
EMA workshop on clinical investigation of new medicines for the treatment of multiple sclerosis current event overview and discussion.
-
EMA guidance · 2013-06-20Registration open for workshop on the clinical investigation of medicines for the treatment of multiple sclerosis
EMA announces registration is open for a workshop focused on the clinical investigation of medicines for multiple sclerosis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA guidance · 2012-10-09European Medicines Agency invites feedback on the draft guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis
EMA invites feedback on a draft guideline outlining clinical investigation considerations for medicinal products intended to treat multiple …
-
EMA guidance · 2012-04-20European Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya
EMA provides new guidance to better manage the risk of heart-related adverse effects with Gilenya (fingolimod).